Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases in the United States and Europe.
It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine technologies, toll-Like receptor activating adjuvants, natural killer cells, and damage-associated molecular patterns inducers.
The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV.
It has collaboration agreements with National Cancer Institute and Amyris, Inc.; and license agreements with LadRx Corporation, GlobeImmune, Inc., Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company is based in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 11, 24 | -0.20 Increased by +25.93% | -0.16 Decreased by -25.00% |
| Mar 19, 24 | -0.35 Decreased by -29.63% | -0.18 Decreased by -94.44% |
| Nov 9, 23 | -0.19 Increased by +32.14% | -0.25 Increased by +24.00% |
| Aug 8, 23 | -0.32 Decreased by -33.33% | -0.23 Decreased by -39.13% |
| May 11, 23 | -0.27 Decreased by -3.85% | -0.27 |
| Mar 1, 23 | -0.27 Decreased by -17.39% | -0.22 Decreased by -22.73% |
| Nov 9, 22 | -0.28 Decreased by -27.27% | -0.23 Decreased by -21.74% |
| Aug 8, 22 | -0.24 Decreased by -4.35% | -0.24 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 82.00 K Decreased by -30.51% | -95.58 M Increased by +13.84% | Decreased by -116.56 K% Decreased by -23.98% |
| Jun 30, 23 | 41.00 K Increased by +17.14% | -137.88 M Decreased by -45.77% | Decreased by -336.29 K% Decreased by -24.44% |
| Mar 31, 23 | 360.00 K Increased by +2.47 K% | -151.16 M Decreased by -47.01% | Decreased by -41.99 K% Increased by +94.28% |
| Dec 31, 22 | 73.00 K Decreased by -81.28% | -108.33 M Decreased by -18.70% | Decreased by -148.39 K% Decreased by -534.16% |
| Sep 30, 22 | 118.00 K Increased by +78.79% | -110.94 M Decreased by -26.60% | Decreased by -94.02 K% Increased by +29.19% |
| Jun 30, 22 | 35.00 K Decreased by -89.68% | -94.59 M Decreased by -7.14% | Decreased by -270.25 K% Decreased by -937.69% |
| Mar 31, 22 | 14.00 K Decreased by -89.93% | -102.83 M Decreased by -29.16% | Decreased by -734.47 K% Decreased by -1.18 K% |
| Dec 31, 21 | 390.00 K Increased by +365.31% | -91.26 M Decreased by -34.66% | Decreased by -23.40 K% Decreased by -150.76% |